Steun en bronnen

We verwijzen naar organisaties en gepubliceerde bronnen die we vertrouwen. igg4.org is onafhankelijk, zonder industriefinanciering of sponsor. Een vermelding hier is een credit, geen poortwachter.

Belangrijkste medische literatuur

De gepubliceerde bronnen achter deze site. Waar mogelijk linken we naar een versie die je volledig kunt lezen, anders naar het publicatierecord. Dit is informatie en vervangt je specialist niet.

1.Della-Torre E, Talarico R, Ballarin J, et al. The five red flags for IgG4-related disease. The Lancet Rheumatology, 2025.
Bron lezen
2.Wallace ZS, Naden RP, Chari S, et al. The 2019 ACR/EULAR classification criteria for IgG4-related disease. Arthritis & Rheumatology, 2020.
Bron lezen
3.Wallace ZS, Katz G, Hernandez-Barco YG, Baker MC. Current and future advances in practice: IgG4-related disease. Rheumatology Advances in Practice, 2024.
Bron lezen
4.Iaccarino L, Talarico R, Scire CA, et al. IgG4-related diseases: state of the art on clinical practice guidelines. RMD Open, 2019.
Bron lezen
5.Sina S, Bonisoli GL, et al. Clinicopathological pearls and diagnostic pitfalls in IgG4-related disease. Diagnostics, 2025.
Bron lezen
6.Maritati F, Peyronel F, Vaglio A. IgG4-related disease: a clinical perspective. Rheumatology, 2020.
Bron lezen
7.Abraham M, Khosroshahi A. Diagnostic and treatment workup for IgG4-related disease. Expert Review of Clinical Immunology, 2017.
Bron lezen
8.Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis & Rheumatology, 2015.
Bron lezen
9.Stone JH, et al. Inebilizumab for treatment of IgG4-related disease. New England Journal of Medicine, 2025.
Bron lezen
10.Cagnotto G, Backlund RT, Bengtsson A, Bruschettini M. Immunosuppressants for IgG4-related disease (protocol). Cochrane Database of Systematic Reviews, 2025.
Bron lezen
11.Cuéllar MC, et al. Enfermedad relacionada a IgG4. Serie clínica de pacientes chilenos. Rev Med Chile 2022;150:705-710.
Bron lezen
12.Lanzillotta M, Campochiaro C, Mancuso G, et al. Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes. Rheumatology (Oxford) 2020;59:2435-2442.
Bron lezen
13.Okazaki K (ed.). IgG4-Related Disease. Current Topics in Microbiology and Immunology, vol. 401. Springer International Publishing, 2017.
Bron lezen
14.Orozco Gálvez O. Enfermedad relacionada con la IgG4: creación de un algoritmo diagnóstico y terapéutico europeo y nuevas técnicas de medicina nuclear. Doctoral thesis, Universitat Autònoma de Barcelona, 2024.
Bron lezen
15.Bateman AC, Culver EL. Challenges and pitfalls in the diagnosis of IgG4-related disease. Seminars in Diagnostic Pathology, 2023.
Bron lezen
16.Reisch M, Spindelböck WJ, Hodl I, Pietsch D, Rainer F, Kickinger D, Sutic A, Thiel J, Stradner M. Azathioprine as maintenance therapy for IgG4-related diseases. Rheumatology International 2026;46(3):47.
Bron lezen
17.Hammitzsch A, Ferraro N, Bachmann Q, Heemann U, Moog P. Long-term treatment patterns and outcomes in IgG4-related disease: a retrospective single-center cohort study focusing on rituximab. Rheumatology International 2026;46:33.
Bron lezen
18.Taranto S, Bernardo L, Mauro A, Perrone A, Tamborino A, Giani T. IgG4-Related Disease in Childhood: Clinical Presentation, Management, and Diagnostic Challenges. Children (Basel) 2025;12(7):888.
Bron lezen
19.González-García A, Starita-Fajardo G, Lucena López D, Iranzo Alcolea MP, et al. New Developments in the Treatment of IgG4-Related Disease: A Comprehensive Clinical Approach. J Clin Med 2025;14(19):6774 (literature searched through July 2025).
Bron lezen
20.Peyronel F, Della-Torre E, Maritati F, Urban ML, Bajema I, Schleinitz N, Vaglio A. IgG4-related disease and other fibro-inflammatory conditions. Nat Rev Rheumatol 2025;21(5):275-290.
Bron lezen
21.Stone JH. IgG4-related disease: lessons from the first 20 years. Rheumatology (Oxford) 2025;64(Suppl 1):i24-i27.
Bron lezen
22.Arias-Intriago M, Gomolin T, Jaramillo F, et al. IgG4-Related Disease: Current and Future Insights into Pathological Diagnosis. Int J Mol Sci 2025;26(11):5325.
Bron lezen
23.Khurram SA, Gueiros LAM, Soares CD, Fonseca FP. IgG4-Related Disease. In: Lymphoproliferative and Granulomatous Disorders of the Oral Cavity. Springer, 2025:207-213.
Bron lezen
24.Hao Q, Lian D, Zhou M, et al. Identification of candidate biomarkers for diagnosis, disease activity, and relapse prediction in IgG4-related disease. Arthritis Res Ther, 2026.
Bron lezen
25.Della-Torre E, Baker MC, Zhang W, et al; INDIGO Trial Investigators. Obexelimab for the Treatment of IgG4-Related Disease. N Engl J Med, published online 2 June 2026.
Bron lezen
26.Stone JH, Carruthers M, Baker MC, et al. A phase 2 trial of rilzabrutinib in IgG4-related disease. Annals of the Rheumatic Diseases, 2026.
Bron lezen
27.Duru N, van der Goes MC, Jacobs JWG, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013;72(12):1905-1913.
Bron lezen
28.Fong AC, Cheung NW. The high incidence of steroid-induced hyperglycaemia in hospital. Diabetes Res Clin Pract 2013.
Bron lezen
29.Nuthalapati M, Menon AR, Rajendran R, et al. IgG4-Related Disease in Urological Practice: A Case Series of Mistaken Malignancies. Indian J Surg Oncol 2025;16(6):1446-1451.
Bron lezen
30.Tomkins M, Martin-Grace J, Kennedy C, et al. Adrenal insufficiency is common amongst kidney transplant recipients receiving maintenance prednisolone and can be predicted using morning cortisol. Nephrol Dial Transplant 2023;38(2):236-245.
Bron lezen
31.Mahajan A, Tinianow A, Katz G. IgG4-Related disease: From diagnosis to remission. Best Practice & Research Clinical Rheumatology 2025;39:102108.
Bron lezen
32.Peng L, Nie Y, Zhou J, et al. Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial. Ann Rheum Dis 2024;83(5):651-660
Bron lezen
33.2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases, European Alliance of Associations for Rheumatology
Bron lezen
34.Choosing Wisely Canada, Allergy and Clinical Immunology recommendations, Canadian Society of Allergy and Clinical Immunology, updated May 2025
Bron lezen
35.Yang F, Wang T, Liu Y. Risk factors for relapse of IgG4-related disease: a systematic review and meta-analysis. Clin Rheumatol 2025;44:4137-4147
Bron lezen
36.Angarola E, Pasqua A, Castro HM, Cáceres A, Spina JC, Casciato P. Clinical characteristics, disease course, and chronic organ damage in a real-world cohort of IgG4-related disease: insights from an Interdisciplinary Unit. Medicina Clínica 2026;166:107317
Bron lezen
37.Peyronel F, Palmisano A, Maritati F, et al. Methotrexate and low-dose prednisone in idiopathic retroperitoneal fibrosis: a randomised clinical trial. J Autoimmun 2025;157:103487
Bron lezen
38.Koster MJ, Ghaffar U, Duong SQ, et al. Incidence, prevalence and mortality of chronic periaortitis: a population-based study. Clin Exp Rheumatol 2022;40:751-757
Bron lezen
39.Dattani R, Barwick TD, El Wardany G, et al; RaDaR Rare Disease Group. An international patient-centred study of retroperitoneal fibrosis. QJM 2022;115(3):148-154
Bron lezen
40.Tang H, Yang H, Zhang P, et al. Malignancy and IgG4-related disease: the incidence, related factors and prognosis from a prospective cohort study in China. Sci Rep 2020;10:4910
Bron lezen
41.So H, Choi SJ, Park S, et al. Increased cancer risk in patients with IgG4-related disease in a nationwide South Korean cohort, 2012-2021. Sci Rep 2025;15:37273
Bron lezen

National clinical guidance

De links hieronder leiden buiten deze site, om je te helpen zelf verder te zoeken. We controleren ze niet en bevelen ze niet aan, en we verdienen niets aan het vermelden ervan. Anders dan onze eigen bronnen hierboven, zijn ze door ons niet gecontroleerd op oorsprong of juistheid. Bevestig belangrijke zaken altijd bij je specialist.

1.Protocole National de Diagnostic et de Soins (PNDS), Maladie associee aux IgG4, Haute Autorite de Sante, FAI2R and CERAINOM-IgG4, November 2025.
Bron lezen

Product information (regulatory)

1.Ficha técnica prednisona, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA
Bron lezen

Patient information from specialist centres

1.Het Oogziekenhuis Rotterdam, IgG4-Gerelateerde Orbitale Ziekte (IgG4-related orbital disease), patient information. Recognised Dutch expertise centre for rare orbital conditions.
Bron lezen
2.Imperial College Healthcare NHS Trust, RPF and IgG4-RD service: specialist multidisciplinary service for retroperitoneal fibrosis and IgG4-related disease.
Bron lezen

Nuttige websites

Achter dit project: ons boek, Balanced Divinity